Oncology Medical News about Myelodysplastic Syndromes Myelodysplastic-Myeloproliferative Diseases

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis
Haematologica, 09/25/09

Gurion R et al. – Since 5–azacitidine prolongs overall survival and time to transformation or death it should be highly considered in the treatment of high risk MDS patients. Further studies are needed to establish the exact role of decitabine compared to 5–azacitidine in these patients.

<< Previous
Genome wide molecular analysis of minimally differentiated acute...

Next >>
Evaluation of bowel cancer registration data in England,...

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
Cancer Management and Research, 10/13/09 Relevance Score: 87%

Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09 Relevance Score: 81%

Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Blood, 10/09/09 Relevance Score: 80%

Clinical activity of laromustine (Onrigin) in hematologic malignancies
Expert Review of Hematology, 10/22/09 Relevance Score: 79%

Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes
Bone Marrow Transplantation, 10/01/09 Relevance Score: 79%